Taysha Gene Therapies Stock Forecast
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 4.49 0.00%
TSHA analyst consensus
Consensus (13 analysts)
none
Avg. price target
$13.00+189.53%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Taysha Gene Therapies (2026-10-09), 13 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $13.00, with a high estimate of $19.00 and a low estimate of $9.00. The average target implies upside of 189.5% from the current price of $4.49.
The spread between the highest and lowest targets is 111.1%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for TSHA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 23% |
| Buy | 10 | 77% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | +100.45% |
| Average target | $13.00 | +189.53% |
| High target | $19.00 | +323.16% |